BR112023019066A2 - Método para selecionar pacientes com hipertensão arterial pulmonar e biomarcador - Google Patents

Método para selecionar pacientes com hipertensão arterial pulmonar e biomarcador

Info

Publication number
BR112023019066A2
BR112023019066A2 BR112023019066A BR112023019066A BR112023019066A2 BR 112023019066 A2 BR112023019066 A2 BR 112023019066A2 BR 112023019066 A BR112023019066 A BR 112023019066A BR 112023019066 A BR112023019066 A BR 112023019066A BR 112023019066 A2 BR112023019066 A2 BR 112023019066A2
Authority
BR
Brazil
Prior art keywords
biomarker
arterial hypertension
pulmonary arterial
selecting patients
selecting
Prior art date
Application number
BR112023019066A
Other languages
English (en)
Inventor
Yuichi Tamura
Original Assignee
Chugai Pharmaceutical Co Ltd
International Univ Of Health And Welfare
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd, International Univ Of Health And Welfare filed Critical Chugai Pharmaceutical Co Ltd
Publication of BR112023019066A2 publication Critical patent/BR112023019066A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

método para selecionar pacientes com hipertensão arterial pulmonar e biomarcador. a presente invenção refere-se a um biomarcador para prever uma responsividade a um tratamento direcionado a uma via de sinalização de il-6, em um paciente com hipertensão arterial pulmonar e a um método de seleção de um paciente.
BR112023019066A 2021-03-25 2022-03-24 Método para selecionar pacientes com hipertensão arterial pulmonar e biomarcador BR112023019066A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021051574 2021-03-25
PCT/JP2022/013767 WO2022202950A1 (ja) 2021-03-25 2022-03-24 肺動脈性肺高血圧症患者の選定方法およびバイオマーカー

Publications (1)

Publication Number Publication Date
BR112023019066A2 true BR112023019066A2 (pt) 2023-10-17

Family

ID=83395767

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023019066A BR112023019066A2 (pt) 2021-03-25 2022-03-24 Método para selecionar pacientes com hipertensão arterial pulmonar e biomarcador

Country Status (10)

Country Link
EP (1) EP4321176A1 (pt)
JP (1) JPWO2022202950A1 (pt)
KR (1) KR20230159522A (pt)
CN (1) CN117043598A (pt)
AU (1) AU2022243842A1 (pt)
BR (1) BR112023019066A2 (pt)
CA (1) CA3212195A1 (pt)
IL (1) IL306073A (pt)
TW (1) TW202305367A (pt)
WO (1) WO2022202950A1 (pt)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6116938B2 (ja) * 2013-02-28 2017-04-19 学校法人順天堂 新規な肺高血圧症のマーカー
KR20170013261A (ko) * 2014-06-03 2017-02-06 노파르티스 아게 폐 고혈압 바이오마커

Also Published As

Publication number Publication date
JPWO2022202950A1 (pt) 2022-09-29
CN117043598A (zh) 2023-11-10
IL306073A (en) 2023-11-01
EP4321176A1 (en) 2024-02-14
TW202305367A (zh) 2023-02-01
AU2022243842A1 (en) 2023-11-09
WO2022202950A1 (ja) 2022-09-29
KR20230159522A (ko) 2023-11-21
CA3212195A1 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
BRPI0507442B8 (pt) método in vitro de diagnóstico de um indivíduo humano gestante como apresentando ou com uma propensão a desenvolver pré-eclâmpsia ou eclâmpsia
Cerezo-Guisado et al. Implication of Akt, ERK1/2 and alternative p38MAPK signalling pathways in human colon cancer cell apoptosis induced by green tea EGCG
MX2023006766A (es) Composiciones que comprenden inhibidores de shp2 y metodos para tratar el cancer.
CY1124697T1 (el) Πρωτεϊνες συντηξης για τη θεραπεια διαταραχων του μεταβολισμου
Chinnaiyan et al. Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma
EA201270100A1 (ru) Пиримидиноны в качестве ингибиторов pi3k
UY30097A1 (es) Usos terapeuticos de inhibidores de rtp801
BR112022009216A2 (pt) Métodos e composições para tratar um distúrbio associado a angiotensinogênio (agt)
BR112015028845A2 (pt) compostos para a modulação da quinase e indicações da mesma
EA201490697A1 (ru) Белки с двойной функцией для лечения метаболических расстройств
BR112012019459A2 (pt) identificação de mutação de lkb1 como um biomarcador preditivo para sensibilidade para inibidores de tor quinase.
BR112015031542A2 (pt) métodos de previsão de reação de pacientes com câncer, método de tratamento de câncer, kit de previsão da reação ao tratamento e processos, métodos e usos inovadores
BR112012011528A2 (pt) métodos para inibir uma proteína quinase e para tratar uma doença associada com atividade de quinase, e, composto
EA201992026A1 (ru) Применение биомаркеров при идентификации пациентов, имеющих рак, которые будут характеризоваться наличием восприимчивости к лечению ингибитором prmt5
EA202092276A2 (ru) Антитело, распознающее лейкемический ингибиторный фактор (lif) человека, и применение антител против lif при лечении заболеваний, связанных с нежелательной пролиферацией клеток
MX2020002553A (es) Metodos de diagnostico y terapeuticos para el cancer.
EA201890891A1 (ru) Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
BR112012007555A2 (pt) biomarcadores para prever a sensibilidade e resposta de doenças mediadas por quinase de proteína ck2 a inibidores de ck2
EA201201113A1 (ru) Способы и соединения для роста мышц
EA202092720A1 (ru) Способ увеличения биологической доступности и степени воздействия активатора потенциалзависимых калиевых каналов
Rajapakse et al. Impaired l-arginine-nitric oxide pathway contributes to the pathogenesis of resistant hypertension
CY1124768T1 (el) Μεθοδος για προβλεψη θεραπευτικης ωφελειας της anti-cd19 θεραπειας σε ασθενεις
Mikuła-Pietrasik et al. Serum from varicose patients induces senescence-related dysfunction of vascular endothelium generating local and systemic proinflammatory conditions
EA201692497A1 (ru) Биомаркеры ответа на ингибиторы ezh2
CO2023007607A2 (es) Métodos, sistemas y equipos para el tratamiento de enfermedades inflamatorias dirigidas al tl1a